Clinical trial · Observational
Ovarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized by hyperandrogenism, insulin resistance, and ovulatory dysfunction. One of the diagnostic criteria for PCOS is the presence of polycystic ovaries, which are enlarged ovaries with multiple follicles on ultrasound. However, the mechanisms that lead to the development of polycystic ovaries in PCOS are not completely understood. One potential area of investigation is the role of ovarian innervation in the pathophysiology of PCOS. Therefore, the aim of this study is to evaluate the ovarian innervation in PCOS patients through ovarian biopsy sampling.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ovary Biopsie | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PCOS women
- description
- Ovarian biopsy will be performed on PCOS women meeting the inclusion criteria undergoing surgery for other reasons . A sample of the ovarian tissue will be of a few millimeters in size and taken on only one of the ovaries.
- interventionNames
- Procedure: Ovary Biopsie
Primary outcomes (2)
- measure
- Quantify nerve fibers
- timeFrame
- day 0
- description
- identify and quantify the nerve fibers in the ovarian stroma and follicles
- measure
- Identifying nerual markers
- timeFrame
- day 0
- description
- Identification of neural markers such as Protein Gene Product 9.5 (PGP 9.5), by useing antibodies (es. neurotransmitters such as tyrosine hydroxylase (TH), vasoactive intestinal peptide (VIP), and neuropeptide Y).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion criteria: * Diagnosis of PCOS based on the Rotterdam criteria, * No use of hormonal contraception or medications for at least 3 months prior to the study, * No history of ovarian cancer. Exclusion Criteria: * History of pelvic inflammatory disease or other pelvic infections, * Use of medications that may affect ovarian function or innervation, such as antipsychotics or antidepressants * Presence of ovarian cysts \> 5 cm on ultrasound
References
Publications (0)
Data not yet available